KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $140.3 million.

  • Alnylam Pharmaceuticals' Free Cash Flow rose 23518.54% to $140.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $465.4 million, marking a year-over-year increase of 119273.05%. This contributed to the annual value of $465.4 million for FY2025, which is 119273.05% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Free Cash Flow stood at $140.3 million for Q4 2025, which was up 23518.54% from $313.0 million recorded in Q3 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Free Cash Flow peaked at $342.3 million during Q3 2023, and registered a low of -$252.8 million during Q1 2021.
  • In the last 5 years, Alnylam Pharmaceuticals' Free Cash Flow had a median value of -$115.5 million in 2024 and averaged -$43.3 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first tumbled by 13003.72% in 2024, then skyrocketed by 69202.08% in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Free Cash Flow stood at -$172.0 million in 2021, then rose by 10.7% to -$153.6 million in 2022, then soared by 70.64% to -$45.1 million in 2023, then tumbled by 130.04% to -$103.8 million in 2024, then soared by 235.19% to $140.3 million in 2025.
  • Its Free Cash Flow was $140.3 million in Q4 2025, compared to $313.0 million in Q3 2025 and $139.4 million in Q2 2025.